Literature DB >> 2651531

In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase.

B Pangon, C Bizet, A Buré, F Pichon, A Philippon, B Regnier, L Gutmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2651531     DOI： 10.1093/infdis/159.5.1005

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  41 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

2.  The Red Menace: Emerging Issues in Antimicrobial Resistance in Gram-Negative Bacilli.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

3.  Countrywide spread of CTX-M-3 extended-spectrum beta-lactamase-producing microorganisms of the family Enterobacteriaceae in Poland.

Authors:  Anna Baraniak; Janusz Fiett; Agnieszka Sulikowska; Waleria Hryniewicz; Marek Gniadkowski
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 4.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 5.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

Review 6.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 7.  Is it important to identify extended-spectrum beta-lactamase-producing isolates?

Authors:  K Bush
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

8.  Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia.

Authors:  J K Rasheed; C Jay; B Metchock; F Berkowitz; L Weigel; J Crellin; C Steward; B Hill; A A Medeiros; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

9.  Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli.

Authors:  H Guet-Revillet; A Emirian; M Groh; B Nebbad-Lechani; E Weiss; O Join-Lambert; E Bille; V Jullien; J R Zahar
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

10.  Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?

Authors:  E S Moland; C C Sanders; K S Thomson
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.